Table 3.

Prevalence of exposure to drug classes with anticholinergic and sedative activity

Therapeutic DBI drug class and most frequently reported medicine within each class	ATC code	% of population exposed, (95% CI; n)
Anticholinergic
Antipsychotics	N05A	44.0 (40.26–47.74; n = 298)
Risperidone	N05AX08	15.7 (12.9–18.4; n = 106)
Antiepileptics	N03A	42.4 (38.68–46.12; n = 287)
Valproic acid	N03AG01	19.4 (16.4–22.3; n = 131)
Antidepressants	N06A	27.8 (24.43–31.17; n = 188)
Escitalopram	N06AB10	5.8 (4.0–7.5; n = 39)
Anticholinergic agents	N04A	13.0 (10.47–15.52; n = 88)
Biperiden	N04AA02	8.7 (6.6–10.8; n = 59)
Anxiolytics	N05B	11.5 (9.1–13.9; n = 78)
Diazepam	N05BA01	6.1 (4.3–7.9; n = 41)
Diuretics	C03(A, C, D)	7.4 (5.43–9.37; n = 55)
Furosemide	C03CA01	5.0 (3.4–6.7; n = 34)
Antihistamines	R06A	5.5 (3.78–7.22; n = 37)
Cetirizine	R06AE07	1.6 (0.7–2.6; n = 11)
Sedative
Hypnotics and sedatives	N05C	7.1 (5.17–9.03; n = 48)
Zopiclone	N05CF01	2.8 (1.6–4.1; n = 19)
Antidementia drugs	N06D	3.4 (2.03–4.77; n = 23)
Donepezil	N06DA02	2.2 (1.1–3.3; n = 15)
Drugs for benign prostate hypertrophy	G04C	1.8 (0.8–2.8; n = 12)
Tamsulosin	G04CA02	1.8 (0.8–2.8; n = 12)

Other therapeutic classes reported by <5% listed in Supporting Information Table S4.